TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04977453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-101
Description: Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-101
Description: Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-101
Description: Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-101
Description: Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: Pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: Pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered at an approved dose orally.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local Radiotherapy
Description: Patients will receive SBRT prior to the first dose of GI-101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-101A
Description: Recommended phase 2 dose of GI-101A will be administered via IV infusion Q3W up to 2 years (approximately 35 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-101A
Description: Recommended phase 2 dose of GI-101A will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Study: NCT05945121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardio-oncology program
Description: Consented patients will undergo an initial CV evaluation as part of standard of care then participate in an 8-week at-home, personalized exercise intervention followed by an additional CV assessment prior to HSCT (after 8-weeks)
Study: NCT06444308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CommCare with Mobile Clinical Decision Support (CDS) Application
Description: For those assigned to the CHW arm, management will be assisted by CDS from the CommCare application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Supervision by Physicians
Description: teleconsultation with a supervising physician

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CommCare Application without CDS
Description: The physician will have received training and orientation on the same clinical protocols followed by the CHWs, as well as access to reference materials for these protocols, but the version of the CommCare application used will not provide CDS, but will serve to record and review patient data only.
Study: NCT05914623

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: After enrollment, the patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: After enrollment, the patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
Study: NCT05089019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selpercatinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally
Study: NCT06508333

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: alarm therapy
Description: These patients will receive alarm therapy for 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: alarm therapy
Description: These patients will receive alarm therapy for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: These patients will receive high-dose vitamin D supplementation (more than 2000IU daily) (combined with alarm therapy) for 8 weeks.
Study: NCT04837443

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Rubber hand illusion
Description: Tactile sensory threshold from quantitative sensory tests, two point discrimination from cortical senses, pressure pain threshold measured by algometer will be examined during and after the rubber hand burning, which causes changes in body perception.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rubber hand illusion
Description: Tactile sensory threshold from quantitative sensory tests, two point discrimination from cortical senses, pressure pain threshold measured by algometer will be examined during and after the rubber hand burning, which causes changes in body perception.
Study: NCT06423547

Intervention type: OTHER
Intervention: no intervention
Description: this is an observation study,no intervention
Study: NCT04638088

Intervention type: OTHER
Intervention: assessment of urinary function and erectil function before and after prostatectomy
Description: assessment of urinary function and erectil function before and after prostatectomy performed by robot assisted or conventional laparoscopy or laparotomy will complete

Intervention type: OTHER
Intervention: assessment of urinary function and erectil function before and after prostatectomy
Description: assessment of urinary function and erectil function before and after prostatectomy performed by robot assisted or conventional laparoscopy or laparotomy will complete

Intervention type: OTHER
Intervention: assessment of urinary function and erectil function before and after prostatectomy
Description: assessment of urinary function and erectil function before and after prostatectomy performed by robot assisted or conventional laparoscopy or laparotomy will complete
Study: NCT05975827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sterile Wound Care Liquid Dressing
Description: Sterile wound care liquid dressing is used in the wound treatment
Study: NCT05518500

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Vaccine (Year 1)
Description: Participants will receive Fluzone® Quadrivalent High-Dose in the 2022-2023 flu season.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Vaccine (Year 2)
Description: Participants will receive FLUAD® Quadrivalent in the 2023-2024 flu season.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Vaccine (Year 3)
Description: Participants will receive Flublok Quadrivalent in the 2024-2025 flu season.
Study: NCT06318143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TASSH
Description: Strategy for Hemoglobinopathies (TASSH) containing the essential components of i) Training healthcare workers/providers to be more patient-centered in clinical consultations, ii) Clinical reminders, and iii) Practice facilitation (TCP) known as (TASSH TCP) for SCD management (Figure 1A describes the components of the intervention).
Study: NCT04907058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: novel device with a comfortable mask
Description: Using a device with a comfortable mask to supply constant low dose CO2 to treat patients.
Study: NCT05804591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: Single dose of pregabalin 150mg in a capsule per os 1 hour before start of the operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule containing placebo per os 1 hour before start of the operation.
Study: NCT06493552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEphB4-HSA
Description: A recombinant protein comprised of the soluble form of human receptor EphB4 fused to human serum albumin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEphB4-HSA
Description: A recombinant protein comprised of the soluble form of human receptor EphB4 fused to human serum albumin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Antibody to human PD-1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Antibody to human PD-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Antibody to human PD-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Antibody to human PD-1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: A chemotherapy drug used to treat various types of cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: A type of chemotherapy drug called an alkylating agent used to treat various types of cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enfortumab vedotin
Description: Nectin-4-directed antibody and microtubule inhibitor conjugate.
Study: NCT04777799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: URGOnight
Description: URGOnight is a daytime brain training solution (CE marked) aim at improve the quality of sleep. The device consists of an electroencephalographic (EEG) measuring strip connected to a mobile application. The latter is available free of charge on Android and iOS in various mobile application stores (Google Play Store and App Store).~URGOnight is a wireless device, it connects via Bluetooth® Low Energy (BLE) to the URGOnight mobile application running on a smartphone. The EEG data is broadcast via a BLE protocol, and the standard Bluetooth® operating distance has a range of 10 meters.~To use the URGOnight solution, the user must authorize the application to access his phone's memory to store his usage data and must also authorize the geolocation of his phone to enable BLE connection. This data is not recorded but is necessary for the proper functioning of the solution.
Study: NCT06453746

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based cognitive training exercises
Description: The subjects received (i) education on lifestyle modification, (ii) home-based cognitive training exercises with physiotherapist/ physiatrist contact when needed and (iii) a physical training exercises conducted at hospital under the supervision of physiotherapist/ physiatrist (3 weekly session for 12 weeks).~This arm has a duration of 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised cognitive training exercises
Description: The subjects received (i) education on lifestyle modification, (ii) supervised cognitive training exercises at hospital (1 weekly session for 12 weeks) and (iii) a physical training exercises conducted in a hospital under the supervision of physiotherapist/ physiatrist (3 weekly session for 12 weeks).~This arm has a duration of 12 weeks.
Study: NCT06143566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypill
Description: A combination of finerenone 10 mg, empagliflozin 12.5 mg, and losartan 50 mg or 100 mg within a polycapsule.
Study: NCT03994081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS
Description: XCSITE100

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tACS
Description: XCSITE100
Study: NCT06521749

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: USB as a stylet
Description: USB used as a bougie

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: USB as a bougie
Description: USB used as a bougie
Study: NCT06269120

Intervention type: DRUG
Intervention: Oral Semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician.
Study: NCT06498206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AR training
Description: Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in unilateral amblyopia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: Conventional patching therapy.
Study: NCT05411016

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered single dose or multiple dose by IV or SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KK4277
Description: KK4277 is administered single dose or multiple dose by IV or SC injection
Study: NCT06474676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy
Description: Given by IV
Study: NCT05026333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Stress Testing
Description: Cognitive and stress study with no product intervention and noninvasive. The high stress/anxiety group will be compared to the low stress/anxiety group in terms of changes from baseline to after the cognitive and stress tests (i.e., 4 laboratory tasks) and metabolite measures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Stress Testing
Description: Cognitive and stress study with no product intervention and noninvasive. The high stress/anxiety group will be compared to the low stress/anxiety group in terms of changes from baseline to after the cognitive and stress tests (i.e., 4 laboratory tasks) and metabolite measures.
Study: NCT06522256

Intervention type: PROCEDURE
Group type: OTHER
Intervention: High-resolution anoscopy
Description: The study includes 2 visits:~* a medical consultation for inclusion~* a proctology consultation including the performance of an AHR associated or not with biopsy sampling
Study: NCT05325736

Intervention type: PROCEDURE
Intervention: sleeve gastrectomy surgery
Description: participants undergoing sleeve gastrectomy surgery

Intervention type: PROCEDURE
Intervention: gastric bypass surgery
Description: participants undergoing gastric bypass surgery

Intervention type: PROCEDURE
Intervention: control
Description: cholecystectomy
Study: NCT06226129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopiclenol
Description: Gadopiclenol for contrast enhanced MRI
Study: NCT06474455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9839 ；SHR-A2009
Description: SHR-9839 combined with SHR-A2009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9839 ； SHR-A1921
Description: SHR-9839 combined with SHR-A1921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9839 ； pemetrexed ；carboplatin
Description: SHR-9839 combined with pemetrexed + carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9839 ； Almonertinib
Description: SHR-9839 combined with Almonertinib
Study: NCT06281132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-341, D956
Description: A single dose of 1 tablet under fasting condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-341, D956
Description: A single dose of 1 tablet under fasting condition
Study: NCT04834661

Intervention type: OTHER
Intervention: surgery inside the primary institution
Description: to perform laparoscopic surgery for colorectal and gastric cancer inside the primary registered medical institution

Intervention type: OTHER
Intervention: surgery outside the primary institution
Description: to perform laparoscopic surgery for colorectal and gastric cancer outside the primary registered medical institution
Study: NCT05032040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vudalimab
Description: Monoclonal bispecific antibody
Study: NCT05495815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 months of SAT
Description: 6 months of oral suppressive antibiotic therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12 months of SAT
Description: 12 months of oral suppressive antibiotic therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indefinite SAT
Description: Indefinite oral suppressive antibiotic therapy
Study: NCT04798183

Intervention type: DIAGNOSTIC_TEST
Intervention: 3-dimensional scan
Description: Facial 3-dimensional scan according to posture

Intervention type: DIAGNOSTIC_TEST
Intervention: 3-dimensional scan
Description: Facial 3-dimensional scan according to posture
Study: NCT05349591

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cePolytreg
Description: The treatment group will receive cePolyTregs 2 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
Study: NCT05471076

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b 30 mcg
Description: Administered via injection as a split dose into the deltoid muscle (both left and right).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b 30 mcg
Description: Administered via injection as a split dose into the deltoid muscle (both left and right).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b 100 mcg
Description: Administered via injection as a split dose into the deltoid muscle (both left and right).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b 100 mcg
Description: Administered via injection as a split dose into the deltoid muscle (both left and right).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b 100 mcg
Description: Administered via injection as a split dose into the deltoid muscle (both left and right).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b 100 mcg
Description: Administered via injection as a split dose into the deltoid muscle (both left and right).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b 300 mcg
Description: Administered via injection as a split dose into the deltoid muscle (both left and right).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b 300 mcg
Description: Administered via injection as a split dose into the deltoid muscle (both left and right).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via injection as a split dose into the deltoid muscle (both left and right).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via injection as a split dose into the deltoid muscle (both left and right).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505
Description: A soluble, cleavage-competent, trimeric HIV-1 envelope glycoprotein gp140 formulated at 2 mg/mL, 0.55 mL per vial, in 20 mM Tris, 100 mM NaCl, pH 7.5 will be admixed with 3M-052-AF (5 mcg) + Alum (500 mcg
Study: NCT04756427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Citrate 4% Inj Syringe 3Ml
Description: 3 ml of sodium citrate 4% locking solution instilled into the central catheter daily during the period that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to resuming infusion of parenteral nutrition
Study: NCT06213571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Participate in exercise coaching sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in home-based exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive resistance band and exercise booklets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Participate in sessions remotely
Study: NCT06106360

Intervention type: DEVICE
Intervention: Locus Health iPhone App
Description: In this pilot study patients are enrolled into three (3) different groups which will vary by the frequency of the queries being sent to the patients during their chemotherapy cycle. The patients will be separated into three groups of 33-34 patients each. Each group will have a different frequency of symptom questions sent to them via the Locus Health iPhone App to determine patient fatigue and the compliance impact of different query cadences. Patients will be assigned to these 3 groups sequentially since the platform could not assign patients to these three cohorts in a random manner.
Study: NCT05552846

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiotherapy
Description: Four courses of carboplatin/etoposide/anti-PD-1/PD-L1 every 3 weeks All the enrolled patients will be patients with ES-SCLC who did not have PD (determined as per the RECIST v1.1) after 6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, thoracic radiotherapy of 45 Gy/15 fractions. PD-1/PD-L1 maintenance therapy concurrently and after thoracic radiotherapy at least more than 6 months, or until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
Study: NCT06206447

Intervention type: PROCEDURE
Intervention: Tunnel-cuffed Catheter
Description: Tunnel-cuffed Catheter in right internal jugular vein

Intervention type: PROCEDURE
Intervention: Non-ccuffed Catheter
Description: Non-ccuffed Catheter in right internal jugular vein
Study: NCT05552287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks till week 24 (end of study). IFX trough levels will be measured at weeks 4, 12, and 24. During the maintenance, the IFX dose and/or interval adjustments, the IFX discontinuation or the start of a co-medication (i.e., an immunomodulator) will be possible on indication (i.e., primary nonresponse, secondary loss of response, intolerance to study medication) at the physicians' discretion.
Study: NCT04640025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib
Description: Participants will self-administer itacitinib orally using intact tablets with water and without regard to food.
Study: NCT06032871

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high frequency chest wall oscillation
Description: Patients receive airway clearance by high frequency chest wall oscillation for 30 minutes twice a day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Description: Participants received chest physiotherapy twice a day